XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March 31, 2025 were as follows:
Three Months Ended
March 31,
2025
Pfizer Inc.78 %
Other license agreements22 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
March 31,
2025		December 31,
2024		March 31,
2024		December 31,
2023
Cash and cash equivalents$25,180 $41,918 $54,417 $45,204 
Current restricted cash— — 916 — 
Non-current restricted cash1,500 1,500 — 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$26,680 $43,418 $55,333 $46,704 
Restrictions on Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
March 31,
2025		December 31,
2024		March 31,
2024		December 31,
2023
Cash and cash equivalents$25,180 $41,918 $54,417 $45,204 
Current restricted cash— — 916 — 
Non-current restricted cash1,500 1,500 — 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$26,680 $43,418 $55,333 $46,704